Fostamatinib (Tavalisse)

CADTH recommends that Tavalisse not be reimbursed by public drug plans for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP). Evidence from 2 clinical trials showed that after 24 weeks of treatment, Tavalisse was only modestly effective in increasing the likelihood of achieving a sustained platelet count greater than 50,000/µL; in addition, treatment with Tavalisse did not significantly reduce bleeding occurrence or severity compared to placebo, and whether treatment with Tavalisse improves health-related quality of life (HRQoL) is not known. Patients identified a need for treatments that can reduce symptoms and bleeding events and improve other quality of life measures; there was not enough evidence to show that Tavalisse would meet this need.